An oral dosage form has the following: an amount of minocycline selected from the group consisting of 55 mg, 80 mg, and 105 mg; an amount of lactose monohydrate; an amount of hydroxypropylmethylcellulose. The hydroxypropylmethylcellulose is at least 8.3 to about 9.8% hydroxypropoxylated. The minocycline in the oral dosage form has a dissolution profile or release rates about 35% to about 50% in 1 hour, about 60% to about 75% in 2 hours, and at least about 90% in 4 hours. There is also provided a method of treating acne in a human and a method of assisting a physician in prescribing a dose of minocycline for the treatment of acne.
A61K 9/52 - Préparations en capsules, p. ex. de gélatine, de chocolat du type à libération prolongée ou discontinue
A61K 9/54 - Préparations en capsules, p. ex. de gélatine, de chocolat du type à libération prolongée ou discontinue contenant des particules distinctes avec des revêtements de différentes épaisseurs ou de différents matériaux
Apparatus and methods for delivering electromagnetic energy to a patient's tissue with a reduction in the pain experienced by the patient. The tissue treatment apparatus includes a delivery device configured to transfer electromagnetic energy through the skin surface to a region of tissue and a vibration device mechanically coupled with the delivery device. The vibration device is configured to transfer mechanical vibrations through the skin surface to the region of tissue.
A61B 18/04 - Instruments, dispositifs ou procédés chirurgicaux pour transférer des formes non mécaniques d'énergie vers le corps ou à partir de celui-ci par chauffage
A61B 18/18 - Instruments, dispositifs ou procédés chirurgicaux pour transférer des formes non mécaniques d'énergie vers le corps ou à partir de celui-ci par application de radiations électromagnétiques, p. ex. de micro-ondes
A61H 23/02 - Massage par percussion ou vibration, p. ex. en utilisant une vibration ultrasoniqueMassage par succion-vibrationMassage avec des membranes mobiles à entraînement électrique ou magnétique
Ophthalmic composition that includes 0.05% w/v to 2% w/v diglycine or a salt thereof; 0.01 ppm to 3 ppm poly(hexamethylene biguanide); 1 ppm to 10 ppm α-[4-tris(2-hydroxyethyl)ammonium chloride-2-butenyl]poly[1-dimethylammonium chloride-2-butenyl]-ω-tris(2-hydroxyethyl)ammonium chloride; and 0.1% w/v to 2% w/v of one or more boron buffering compounds.
The present invention relates to polymeric compositions useful in the manufacture of biocompatible medical devices. More particularly, the present invention relates to certain monoethylenically unsaturated polymerizable group containing polycarbosiloxane monomers capable of polymerization to form polymeric compositions having desirable physical characteristics useful in the manufacture of ophthalmic devices.
C08F 236/20 - Copolymères de composés contenant plusieurs radicaux aliphatiques non saturés et l'un au moins contenant plusieurs liaisons doubles carbone-carbone le radical ne contenant que deux doubles liaisons carbone-carbone non conjuguées
C08F 30/08 - Homopolymères ou copolymères de composés contenant un ou plusieurs radicaux aliphatiques non saturés, chaque radical ne contenant qu'une seule liaison double carbone-carbone et contenant du phosphore, du sélénium, du tellure ou un métal contenant un métal contenant du silicium
C07F 7/08 - Composés comportant une ou plusieurs liaisons C—Si
C08G 77/50 - Composés macromoléculaires obtenus par des réactions créant dans la chaîne principale de la macromolécule une liaison contenant du silicium, avec ou sans soufre, azote, oxygène ou carbone dans lesquels au moins deux atomes de silicium, mais pas la totalité, sont liés autrement que par des atomes d'oxygène par des liaisons au carbone
C08G 77/20 - Polysiloxanes contenant du silicium lié à des groupes aliphatiques non saturés
5.
Non-volatile dynamic random access memory system with non-delay-lock-loop mechanism and method of operation thereof
A method of operation of a non-volatile dynamic random access memory system including: accessing a dynamic random access memory; managing a delay-locked-loop control in the dynamic random access memory; sourcing timing inputs to the dynamic random access memory by a control logic unit with the delay-locked-loop control disabled including: selecting a back-up interface through a first multiplexer and a second multiplexer, asserting an on-board termination, and accessing data in the dynamic random access memory by the control logic unit at a lower frequency; and enabling a memory control interface by the control logic unit, with the delay-locked-loop control enabled including: selecting a host interface through the first multiplexer, the second multiplexer, or a combination thereof, disabling the on-board termination, and accessing the data in the dynamic random access memory by the memory control interface at a delay-locked-loop frequency.
G11C 14/00 - Mémoires numériques caractérisées par des dispositions de cellules ayant des propriétés de mémoire volatile et non volatile pour sauvegarder l'information en cas de défaillance de l'alimentation
6.
Pharmaceutical compositions comprising mushroom-based polysaccharides and uses thereof
A61K 31/715 - Polysaccharides, c.-à-d. ayant plus de cinq radicaux saccharide liés les uns aux autres par des liaisons glycosidiquesLeurs dérivés, p. ex. éthers, esters
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/573 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p. ex. prégnane ou progestérone substitués en position 21, p. ex. cortisone, dexaméthasone, prednisone ou aldostérone
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A packaged, sterilized intraocular lens prepared by a process comprising providing a hydrophobic acrylic, or low water acrylic, intraocular lens and positioning the acrylic lens in a lens enclosure with an aqueous solution to provide a lens package. The lens package is then heated to a temperature sufficient for sterilization, however, the heating of the lens package must begin before the acrylic lens reaches an equilibrated, hydrated state following contact of the lens with the aqueous solution. The resulting sterilized acrylic intraocular lens will have less than sixty percent of total volume of disc-like features, or less than forty percent of total volume of water vacuoles, after 60 days following sterilization compared to an acrylic lens of the same composition, which was sterilized under the same conditions, but in an equilibrated, hydrated state.
A61L 2/00 - Procédés ou appareils de désinfection ou de stérilisation de matériaux ou d'objets autres que les denrées alimentaires ou les lentilles de contactAccessoires à cet effet
B29D 11/00 - Fabrication d'éléments optiques, p. ex. lentilles ou prismes
Ophthalmic composition that includes 0.05% w/v to 2% w/v diglycine or a salt thereof; 1.0 ppm to 8.5 ppm alexidine, and 0.1% w/v to 2% w/v of one or more boron buffering compounds.
An illumination system for illuminating a first biologic substance and a second biologic substance, comprising a first light output device capable of outputting polychromatic first light, a second light output device capable of outputting polychromatic second light, the first light output device and the second light output device selected such that (i) a first apparent color results when the first light is scattered from the first biologic substance and a second apparent color results when the second light is scattered from the first biologic substance, the first apparent color and the second apparent color being substantially the same as one another and (ii) a third apparent color results when the first light is scattered from the second biologic substance and a fourth apparent color results when the second light is scattered from the second biologic substance, the third apparent color and the fourth apparent color being substantially different than one another, and means for temporally modulating amounts of the first light and amounts of the second light in a light output from the system.
A61B 5/05 - Détection, mesure ou enregistrement pour établir un diagnostic au moyen de courants électriques ou de champs magnétiquesMesure utilisant des micro-ondes ou des ondes radio
F21V 9/00 - Éléments modifiant les caractéristiques spectrales, la polarisation ou l’intensité de la lumière émise, p. ex. filtres
G01N 21/29 - CouleurPropriétés spectrales, c.-à-d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en utilisant la détection visuelle
11.
Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts
Pharmaceutical formulations and methods for the topical or transdermal delivery of 1isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5 c]quinolin-4-amine, i.e., imiquimod, to treat genital/perianal warts with shorter durations of therapy than currently prescribed for the commercially available for Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating genital/perianal warts with an acceptable safety profile and dosing regimens that are shorter and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat genital/perianal warts are also disclosed and described.
Pharmaceutical formulations and methods for the topical and/or transdermal delivery of imiquimod, including creams, ointments and pressure-sensitive adhesive compositions to treat dermatological disorders, namely, viral infections, such as Type I or Type II Herpes simplex infections and genital and perianal warts, actinic keratosis and superficial basal cell carcinoma, and to induce interferon biosynthesis to achieve an antiviral effect, with shorter durations of therapy, than currently approved for imiquimod by the Food & Drug Administration (“FDA”).
A01N 43/42 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés hétérocycliques comportant des cycles avec un atome d'azote comme unique hétéro-atome du cycle des cycles à six chaînons condensés avec des carbocycles
A61K 31/44 - Pyridines non condenséesLeurs dérivés hydrogénés
C07D 235/02 - Composés hétérocycliques contenant des cycles diazole-1, 3 ou diazole-1, 3 hydrogéné, condensés avec d'autres cycles condensés avec des carbocycles ou avec des systèmes carbocycliques
Disclosed is a process for making vinyl chloroformate which includes reacting (a) a carbonyl compound of formula I:
wherein R is a halogen or an alkyl group of 1 to about 25 carbon atoms; with (b) a silyl-containing enol ether and in the presence of an effective amount of a Group VIII-containing catalyst.
A handheld apparatus for delivering optical energy to fractionally resurface skin of a consumer is configured to be used by the non-physician consumer. The handheld apparatus includes a housing dimensioned for manual grasping and manipulation. The housing encloses a laser and an optical pattern generator having a rotatable component with a plurality of reflective segments that rotate through an optical beam from the laser to deflect and divide the optical beam into pulses that propagate from the housing and form a fractional pattern at the skin surface. The handheld apparatus also includes a transducer associated with fins on the rotatable component to generate signals for each pulse of electromagnetic radiation, the signals being monitored by a controller to enable an end of dose indication for the consumer when the treatment is completed.
Compositions for treating, reducing, ameliorating, or preventing infections comprise a fluoroquinolone having Formulae I-VIII and an additional anti-infective agent. Methods for treating, reducing, ameliorating, or preventing such infection use such compositions. Such compositions and methods can be effective against mixed types of pathogens including certain antibiotic-resistant microbial pathogens found in such infections.
A61K 31/55 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole
A61K 39/40 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire bactériens
C07D 243/08 - Composés hétérocycliques contenant des cycles à sept chaînons comportant deux atomes d'azote comme uniques hétéro-atomes du cycle les atomes d'azote étant en positions 1, 4 non condensés avec d'autres cycles
A system detects whether a pneumatic surgical instrument is attached to a surgical system. A drive valve has an input for connection to a source of pressurized air, an output for connection to the surgical instrument, and an exhaust for exhausting pressurized air during operation of the surgical instrument. A pressure transducer in communication with the exhaust senses a pressure profile of air flow from the exhaust. A first sensed pressure profile indicates that the surgical instrument is connected to the output and a second sensed pressure profile indicates that the surgical instrument is not connected to the output. A detection circuit connected to an output of the pressure transducer detects whether the surgical instrument is attached to the surgical system based on the sensed pressure profile.
An ophthalmic device is disclosed that is a polymerization product of a monomeric mixture comprising (a) a major amount of a non-silicone-containing hydrophilic monomer; (b) a hydrophobic monomer; and (c) a crosslinking agent, wherein the ophthalmic device has an equilibrium water content of at least about 70 weight percent and further wherein the ophthalmic device has an evaporative dehydration barrier layer on the surface thereof. A method for the mitigation of evaporative corneal dehydration employing the high water content ophthalmic device is also disclosed.
G02B 1/04 - Éléments optiques caractérisés par la substance dont ils sont faitsRevêtements optiques pour éléments optiques faits de substances organiques, p. ex. plastiques
Compositions for treating, reducing, ameliorating, or preventing infections comprise a fluoroquinolone having Formulae I-VIII and an additional anti-infective agent. Methods for treating, reducing, ameliorating, or preventing such infection use such compositions. Such compositions and methods can be effective against mixed types of pathogens including certain antibiotic-resistant microbial pathogens found in such infections.
A61K 31/55 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole
A61K 39/40 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire bactériens
C07D 243/08 - Composés hétérocycliques contenant des cycles à sept chaînons comportant deux atomes d'azote comme uniques hétéro-atomes du cycle les atomes d'azote étant en positions 1, 4 non condensés avec d'autres cycles
A method for operating a dynamic back-up storage system includes: providing a high speed memory including a first rank memory device and subsequent ranks of memory devices; providing a non-volatile memory for saving data from the high speed memory; and providing a control logic unit for controlling access, of a central processing unit that executes a program, from the high speed memory including restoring the subsequent ranks of memory devices while the central processing unit is executing the program from the first rank memory device.
G06F 13/16 - Gestion de demandes d'interconnexion ou de transfert pour l'accès au bus de mémoire
G06F 12/06 - Adressage d'un bloc physique de transfert, p. ex. par adresse de base, adressage de modules, extension de l'espace d'adresse, spécialisation de mémoire
Biomedical devices such as silicone hydrogels formed from a polymerization product of a mixture comprising (a) a siloxane-containing homopolymer which has only one thio carbonyl thio fragment of a reversible addition fragmentation chain transfer (RAFT) agent; and (b) one or more biomedical device-forming comonomers are disclosed.
A brimonidine pamoate polymorph exhibits characteristics disclosed herein, wherein the brimonidine pamoate has the following formula
The polymorph is included in a composition, device, or implant for use in the treatment or control of elevated intraocular pressure or in the neuroprotection of components of a neurological tissue to prevent progressive degeneration of such components. In particular, such a composition, device, or implant can be used to provide neuroprotection to cells and components of the optic nerve system.
A61K 31/495 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec deux azote comme seuls hétéro-atomes d'un cycle, p. ex. pipérazine
Crosslink agents used to copolymerize at least one hydrophilic monomer with at least one lens monomer typically used to prepare polymeric materials for ophthalmic lenses. The crosslink agents have a relatively high selectivity for the hydrophilic monomer and limited reactivity with the crosslink agent used to polymerize the lens monomer. Accordingly, the invention is also directed to a hydrophilic crosslinked polymer that comprises at least two monomeric units and at least two different crosslink units. The use of the dual crosslink system provides an improved means to control the final chemical, physical and structural characteristics of the resulting polymer.
C07C 69/602 - Esters d'acides dicarboxyliques avec plusieurs liaisons doubles carbone-carbone
C07C 211/36 - Composés contenant des groupes amino liés à un squelette carboné ayant des groupes amino liés à des atomes de carbone de cycles autres que des cycles aromatiques à six chaînons d'un squelette carboné saturé contenant au moins deux groupes amino liés au squelette carboné
26.
Ophthalmic surgery kits for priming tubes for ophthalmic surgical procedures
An ophthalmic surgery kit includes a priming vessel defining a reservoir for holding a fluid, an auxiliary aspiration channel, an irrigation channel, a handpiece channel, and an ophthalmic surgical handpiece retained by the handpiece channel. The ophthalmic surgical handpiece includes a tip disposed within the reservoir. An auxiliary aspiration tube 15 retained by the auxiliary aspiration channel with a first end disposed within the reservoir. An irrigation tube first end is retained by the irrigation channel within the reservoir.
A61F 9/007 - Procédés ou dispositifs pour la chirurgie de l'œil
A61M 1/00 - Dispositifs de succion ou de pompage à usage médicalDispositifs pour retirer, traiter ou transporter les liquides du corpsSystèmes de drainage
27.
Ophthalmic compositions with biguanide and PEG-glycerol esters
Ophthalmic compositions that comprise 0.1 ppm to 2 ppm of poly(hexamethylene biguanide); and 0.005 wt. % to 0.3 wt. % of a PEG-glycerol ester of general formula I
4alkyl; and x+y+z has an average value from 8 to 30. The invention is also directed to the use of the ophthalmic compositions to clean and disinfect contact lenses, and in particular, soft, silicone hydrogel contact lenses.
Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available ALDARA 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for ALDARA 5% imiquimod cream to treat actinic keratosis are also disclosed and described.
A01N 43/52 - Diazoles-1,3Diazoles-1,3 hydrogénés condensés avec des carbocycles, p. ex. benzimidazoles
A01N 43/42 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés hétérocycliques comportant des cycles avec un atome d'azote comme unique hétéro-atome du cycle des cycles à six chaînons condensés avec des carbocycles
29.
2×2×2 week dosing regimen for treating actinic keratosis with pharmaceutical compositions formulated with 3.75 % imiquimod
Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available ALDARA 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for ALDARA 5% imiquimod cream to treat actinic keratosis are also disclosed and described.
A01N 43/42 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés hétérocycliques comportant des cycles avec un atome d'azote comme unique hétéro-atome du cycle des cycles à six chaînons condensés avec des carbocycles
A01N 43/52 - Diazoles-1,3Diazoles-1,3 hydrogénés condensés avec des carbocycles, p. ex. benzimidazoles
30.
2×2×2 week treatment regimen for treating actinic keratosis with pharmaceutical compositions formulated with 2.5% imiquimod
Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available ALDARA 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for ALDARA 5% imiquimod cream to treat actinic keratosis are also disclosed and described.
A01N 43/42 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés hétérocycliques comportant des cycles avec un atome d'azote comme unique hétéro-atome du cycle des cycles à six chaînons condensés avec des carbocycles
A01N 43/52 - Diazoles-1,3Diazoles-1,3 hydrogénés condensés avec des carbocycles, p. ex. benzimidazoles
An intraocular lens comprises an optic portion having a peripheral edge and at least two haptics. Each haptic is integrated with the peripheral edge of the optic portion by a corresponding haptic integration region. Also, each haptic comprises a distal segment region and a deformation segment region. The distal segment region has an outer distal length bounded by a proximate endpoint and a distal endpoint on an outer surface of the haptic, and is scribed by a distal segment angle α of 20° to 30°. The distal segment angle has a segment origin that lies within a radial segment bound by a radial distance 1.5 mm to 1.9 mm from an optic center and a segment angle θ of from 30° to 45° from a vertical axis. The vertical axis extends through the distal endpoint of at least one haptic and the optic center.
A device for inserting a medicament within a body cavity of a mammal, the device including a cartridge for containing the medicament, the cartridge including a housing, a retractable chamber disposed within the housing and having a lumen sized to contain the medicament, a stationary member disposed within the lumen and having a sized to provide a sliding fit within the lumen to provide for retraction of the retractable chamber about the stationary member upon actuation of the device, and means for retracting the retractable chamber while maintaining the stationary member in a stationary position. The device further includes means for activating the means for retracting the retractable chamber. The device further includes an actuator, the actuator including a handle case having a proximal portion for gripping and a distal portion including means for attaching the actuator to a cartridge.
This invention provides compounds of formula I
4 group is situated ortho to the NHC(═X) group; n=1 or 2; X=O or S; Y is O or S; and q=1 or 0. The invention also provides pharmaceutical compositions comprising compounds of formula I and/or salts, esters, and prodrugs thereof. These compounds modulate the activation and inactivation of potassium channels. The compounds are useful for the treatment and prevention of diseases and disorders—such as seizure disorders—which are affected by modulation of potassium ion channels.
C07C 235/16 - Amides d'acides carboxyliques, le squelette carboné de la partie acide étant substitué de plus par des atomes d'oxygène ayant des atomes de carbone de groupes carboxamide liés à des atomes de carbone acycliques et des atomes d'oxygène, liés par des liaisons simples, liés au même squelette carboné le squelette carboné étant acyclique et saturé ayant l'atome d'azote d'au moins un des groupes carboxamide lié à un atome de carbone d'un cycle aromatique à six chaînons
An improved method of preparing a sugar modified nucleoside analog includes a protocol in which a hydroxy group of a sugar is selectively deprotected and oxidized prior to nucleophilic modification of the corresponding carbonyl group. The modified sugar is then coupled to a heterocyclic base that is modified with a dual nucleophilic reagent in a further step that provides N6-modified adenosine analogs with high stereoselectivity.
A process for sterilizing a solution comprising hyaluronic acid. The process comprises providing an aqueous solution of hyaluronic acid with a weight average molecular weight from 0.6 MDa to 3.6 MDa, and the concentration of the hyaluronic acid is from 0.04% to 0.8% by weight. The aqueous solution also has an ionic strength equivalent to an aqueous concentration of sodium chloride from 3% to 30% by weight. Once the aqueous, high salt, hyaluronic acid solution is prepared the solution is maintained at a temperature from 40° C. to 80° C. for at least 1 hour and not longer than six days. Following the heat treatment step, the aqueous solution is filtered through a sterilization filter medium to provide a sterilized high salt, hyaluronic acid solution.
Novel crosslink agents are described that provide for the copolymerization of at least one hydrophilic monomer with at least one lens monomer typically used to prepare materials for ophthalmic lenses. The new crosslink agents have a relatively high selectivity for the hydrophilic monomer and limited reactivity with the crosslink agent used to polymerize the lens monomer.
G02B 1/04 - Éléments optiques caractérisés par la substance dont ils sont faitsRevêtements optiques pour éléments optiques faits de substances organiques, p. ex. plastiques
B29D 11/00 - Fabrication d'éléments optiques, p. ex. lentilles ou prismes
C07C 271/00 - Dérivés d'acide carbamique, c.-à-d. composés contenant l'un des groupes l'atome d'azote ne faisant pas partie de groupes nitro ou nitroso
Provided herein are compositions including diastereomers in substantially diastereomerically pure form and enantiomers in substantially enantiomerically pure form, and processes for preparing them and converting them to metyrosine.
C07C 221/00 - Préparation de composés contenant des groupes amino et des atomes d'oxygène, liés par des liaisons doubles, liés au même squelette carboné
C07C 223/00 - Composés contenant des groupes amino et —CHO liés au même squelette carboné
C07C 225/00 - Composés contenant des groupes amino et des atomes d'oxygène, liés par des liaisons doubles, liés au même squelette carboné, au moins un des atomes d'oxygène, liés par des liaisons doubles, ne faisant pas partie d'un groupe —CHO, p. ex. aminocétones
C07C 255/43 - Nitriles d'acides carboxyliques ayant des groupes cyano liés à des atomes de carbone acycliques ayant des groupes cyano liés à des atomes de carbone acycliques d'un squelette carboné contenant au moins un cycle aromatique à six chaînons le squelette carboné étant substitué de plus par des atomes d'azote liés par des liaisons simples et n'étant pas liés de plus à d'autres hétéro-atomes le squelette carboné étant substitué de plus par des atomes d'oxygène liés par des liaisons simples
C07C 231/06 - Préparation d'amides d'acides carboxyliques à partir de nitriles par transformation de groupes cyano en groupes carboxamide
C07C 227/20 - Préparation de composés contenant des groupes amino et carboxyle liés au même squelette carboné à partir de composés contenant déjà des groupes amino et carboxyle ou leurs dérivés par des réactions impliquant des groupes amino ou carboxyle, p. ex. hydrolyse d'esters ou d'amides, par formation d'halogénures, de sels ou d'esters par hydrolyse d'acides aminés N-acylés ou de leurs dérivés, p. ex. hydrolyse de carbamates
C07C 237/20 - Amides d'acides carboxyliques, le squelette carboné de la partie acide étant substitué de plus par des groupes amino ayant les atomes de carbone des groupes carboxamide liés à des atomes de carbone acycliques du squelette carboné le squelette carboné contenant des cycles aromatiques à six chaînons
C07C 253/00 - Préparation de nitriles d'acides carboxyliques
C07C 231/12 - Préparation d'amides d'acides carboxyliques par des réactions n'impliquant pas la formation de groupes carboxamide
C07C 249/02 - Préparation de composés contenant des atomes d'azote, liés par des liaisons doubles à un squelette carboné de composés contenant des groupes imino
C07C 251/24 - Composés contenant des atomes d'azote, liés par des liaisons doubles à un squelette carboné contenant des groupes imino ayant des atomes de carbone de groupes imino liés à des atomes de carbone de cycles aromatiques à six chaînons
C07C 227/32 - Préparation d'isomères optiques par synthèse stéréospécifique
C07C 229/36 - Composés contenant des groupes amino et carboxyle liés au même squelette carboné ayant des groupes amino et carboxyle liés à des atomes de carbone acycliques du même squelette carboné le squelette carboné contenant des cycles aromatiques à six chaînons avec au moins un groupe amino et un groupe carboxyle liés au même atome de carbone du squelette carboné
C07C 231/18 - Préparation d'isomères optiques par synthèse stéréospécifique
A method of making a contact lens involves depositing on a portion of a molding surface of a contact lens mold a colorant composition comprising a pigment, a copolymer of 2-hydroxyethylmethacrylate and N-vinylpyrrolidinone, and a crosslinking monomer.
G02B 1/04 - Éléments optiques caractérisés par la substance dont ils sont faitsRevêtements optiques pour éléments optiques faits de substances organiques, p. ex. plastiques
B29D 11/00 - Fabrication d'éléments optiques, p. ex. lentilles ou prismes
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
An illumination device for use in an ophthalmic surgical apparatus, the illumination device including a fiber optic having a proximal end and a connector coupled to the fiber optic. The connector includes one or more of (1) a datum surface disposed a predetermined distance from the proximal end to position the proximal end at a predetermined location within the surgical apparatus, (2) a shutter actuation surface configured and arranged to open a shutter in the surgical apparatus when the connector is being connected to the surgical apparatus, and (3) a visual indicator position to provides a visual indication that the connector is fully inserted into the surgical apparatus. The illumination device may be in a combination with an ophthalmic surgical apparatus.
A61B 18/18 - Instruments, dispositifs ou procédés chirurgicaux pour transférer des formes non mécaniques d'énergie vers le corps ou à partir de celui-ci par application de radiations électromagnétiques, p. ex. de micro-ondes
Methods, apparatus, and systems for transcutaneously treating tissue located beneath a skin surface with electromagnetic energy delivered from a treatment electrode. A portion of the treatment electrode is contacted with the skin surface. While maintaining the contact between the portion of the treatment electrode and the skin surface, the electromagnetic energy is delivered from the treatment electrode in a plurality of power pulses through the skin surface to the tissue over a treatment time with a time gap between each consecutive pair of the pulses to lower a level of pain perceived by a patient.
A61N 5/02 - Thérapie par radiations utilisant des hyperfréquences
A61B 18/18 - Instruments, dispositifs ou procédés chirurgicaux pour transférer des formes non mécaniques d'énergie vers le corps ou à partir de celui-ci par application de radiations électromagnétiques, p. ex. de micro-ondes
A61N 1/40 - Application de champs électriques par couplage inductif ou capacitif
The present invention relates to polymeric compositions useful in the manufacture of biocompatible medical devices. More particularly, the present invention relates to certain monoethylenically unsaturated polycarbosiloxane monomers capable of polymerization to form polymeric compositions having desirable physical characteristics useful in the manufacture of ophthalmic devices.
G02B 1/04 - Éléments optiques caractérisés par la substance dont ils sont faitsRevêtements optiques pour éléments optiques faits de substances organiques, p. ex. plastiques
The present invention relates to polymeric compositions useful in the manufacture of biocompatible medical devices. More particularly, the present invention relates to certain monoethylenically unsaturated polycarbosiloxane monomers capable of polymerization to form polymeric compositions having desirable physical characteristics useful in the manufacture of ophthalmic devices.
The present invention relates to polymeric compositions useful in the manufacture of biocompatible medical devices. More particularly, the present invention relates to certain monoethylenically unsaturated polymerizable group containing polycarbosiloxane monomers capable of polymerization to form polymeric compositions having desirable physical characteristics useful in the manufacture of ophthalmic devices.
C08L 43/04 - Homopolymères ou copolymères de monomères contenant du silicium
C08F 236/02 - Copolymères de composés contenant plusieurs radicaux aliphatiques non saturés et l'un au moins contenant plusieurs liaisons doubles carbone-carbone le radical ne contenant que deux doubles liaisons carbone-carbone
The invention is generally directed to the field of image processing, and more particularly to a method and an apparatus for determining a wavefront of an object, in particular a human eye. The invention discloses a method and an apparatus for real-time wavefront sensing of an optical system utilizing two different algorithms for detecting centroids of a centroid image as provided by a Hartmann-Shack wavefront sensor. A first algorithm detects an initial position of all centroids and a second algorithm detects incremental changes of all centroids detected by said first algorithm.
G06K 9/00 - Méthodes ou dispositions pour la lecture ou la reconnaissance de caractères imprimés ou écrits ou pour la reconnaissance de formes, p.ex. d'empreintes digitales
G01J 1/20 - Photométrie, p. ex. posemètres photographiques par comparaison avec une lumière de référence ou avec une valeur électrique de référence l'intensité de la valeur mesurée ou de référence étant modifiée jusqu' à égalisation de leurs effets au niveau du détecteur, p. ex. en faisant varier l'angle d'incidence
A61B 3/14 - Dispositions spécialement adaptées à la photographie de l'œil
46.
Minocycline oral dosage forms for the treatment of acne
A61K 9/54 - Préparations en capsules, p. ex. de gélatine, de chocolat du type à libération prolongée ou discontinue contenant des particules distinctes avec des revêtements de différentes épaisseurs ou de différents matériaux
A61K 9/52 - Préparations en capsules, p. ex. de gélatine, de chocolat du type à libération prolongée ou discontinue
Biomedical devices such as contact lenses formed from a polymerization product of a mixture comprising an ethylenically unsaturated-containing non-amphiphilic macromonomer comprising hydrophilic units or hydrophobic units derived from a living radical polymerization of one or more ethylenically unsaturated hydrophilic monomers or one or more ethylenically unsaturated hydrophobic monomers are disclosed.
Biomedical devices such as silicone hydrogels formed from a polymerization product of a mixture comprising (a) a siloxane-containing homopolymer comprising one or more thio carbonyl thio fragments of a reversible addition fragmentation chain transfer (RAFT) agent; and (b) one or more biomedical device-forming monomers are disclosed.
Biomedical devices such as contact lenses formed from a polymerization product of a mixture comprising (a) a random copolymer comprising hydrophilic units and hydrophobic units, wherein the random copolymer has at least one thio carbonyl thio fragment of a reversible addition fragmentation chain transfer (“RAFT”) agent are disclosed.
C08F 226/06 - Copolymères de composés contenant un ou plusieurs radicaux aliphatiques non saturés, chaque radical ne contenant qu'une seule liaison double carbone-carbone et l'un au moins étant terminé par une liaison simple ou double à l'azote ou par un hétérocycle contenant de l'azote par un hétérocycle contenant de l'azote
C08F 30/08 - Homopolymères ou copolymères de composés contenant un ou plusieurs radicaux aliphatiques non saturés, chaque radical ne contenant qu'une seule liaison double carbone-carbone et contenant du phosphore, du sélénium, du tellure ou un métal contenant un métal contenant du silicium
C08G 75/00 - Composés macromoléculaires obtenus par des réactions créant dans la chaîne principale de la macromolécule une liaison contenant du soufre, avec ou sans azote, oxygène ou carbone
13C NMR spectrum having peaks at 23.3, 27.7, 41.1, 54.5, 116.6, and 153.5 ppm; and (d) pKa values of 5.65 and 9.91. The compound belongs to the class of fluoroquinolones and is useful as an antibacterial agent.
A61K 31/55 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole
C07D 401/10 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne carbonée contenant des cycles aromatiques
51.
Optical material and method for modifying the refractive index
The invention is directed to an optical device comprising refractive optical structures, wherein the refractive structures are characterized by a change in refractive index, exhibit little or no scattering loss, and exhibit no significant differences in the Raman spectrum with respect to the non-irradiated optical, polymeric material.
A system, method and apparatus for clock and power fault detection for a memory module is provided. In one embodiment, a system is provided. The system includes a voltage detection circuit and a clock detection circuit. The system further includes a controller coupled to the voltage detection circuit and the clock detection circuit. The system also includes a memory control state machine coupled to the controller. The system includes volatile memory coupled to the memory control state machine. The system further includes a battery and battery regulation circuitry coupled to the controller and the memory control state machine. The battery, battery regulation circuitry, volatile memory, memory control state machine, controller, clock detection circuit and voltage detection circuit are all collectively included in a unitary memory module.
The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.
A system, method and apparatus for clock and power fault detection for a memory module is provided. In one embodiment, a system is provided. The system includes a voltage detection circuit and a clock detection circuit. The system further includes a controller coupled to the voltage detection circuit and the clock detection circuit. The system also includes a memory control state machine coupled to the controller. The system includes volatile memory coupled to the memory control state machine. The system further includes a battery and battery regulation circuitry coupled to the controller and the memory control state machine. The battery, battery regulation circuitry, volatile memory, memory control state machine, controller, clock detection circuit and voltage detection circuit are all collectively included in a unitary memory module.
Apparatus and methods for delivering electromagnetic energy to a patient's tissue with a reduction in the pain experienced by the patient. The tissue treatment apparatus includes a delivery device configured to transfer electromagnetic energy through the skin surface to a region of tissue and a vibration device mechanically coupled with the delivery device. The vibration device is configured to transfer mechanical vibrations through the skin surface to the region of tissue.
A61H 1/00 - Appareils pour l'exercice passifAppareils vibrateursDispositifs de chiropractie, p. ex. dispositifs pour appliquer des chocs au corps, dispositifs externes pour étirer ou aligner de façon brève des os non fracturés
A61H 1/02 - Appareils d'exercice extenseurs ou de ployage
Methods, apparatus, and systems for delivering electromagnetic energy to a patient's tissue with a reduction in the pain experienced by the patient. Electromagnetic energy is delivered from a treatment electrode through the skin surface to the tissue at a plurality of power levels over a treatment time. During the energy delivery, a portion of the treatment electrode is in a contacting relationship with the skin surface. A dielectric member may be disposed between the treatment electrode and the skin surface when the electromagnetic energy is delivered.
A61B 18/18 - Instruments, dispositifs ou procédés chirurgicaux pour transférer des formes non mécaniques d'énergie vers le corps ou à partir de celui-ci par application de radiations électromagnétiques, p. ex. de micro-ondes
A61B 18/00 - Instruments, dispositifs ou procédés chirurgicaux pour transférer des formes non mécaniques d'énergie vers le corps ou à partir de celui-ci
An ophthalmic illumination system includes a collimated light beam focused onto an optical fiber for transmission of the light beam to an ophthalmic light probe. A light attenuator includes a pair of arrays positioned serially in a path for the collimated beam. The arrays are movable in parallel in the path about a rotational axis orthogonal to the path and between the arrays. Each array includes a plurality of regularly spaced-apart parallel plates, the parallel plates of one array being non-parallel to the plates of the other array.
G02B 6/00 - Guides de lumièreDétails de structure de dispositions comprenant des guides de lumière et d'autres éléments optiques, p. ex. des moyens de couplage
58.
System to identify viscosity of aspirated material during ophthalmic surgery
An ophthalmic surgical system 10 detects a change in a viscosity of a material being aspirated from an eye 32. The system 10 includes a control module 18 connected to an aspiration pump 20, and a flow meter 19 connected to the control module 18 and the aspiration pump 20. The flow meter 19 provides a flow rate of material aspirated from the eye 32 by the aspiration pump 20. A surgical handpiece 24 connected to the aspiration pump 20 and the control module 18 is inserted into the eye 32 during surgery. The control module 18, during surgery, detects a step change in the flow rate of material aspirated from the eye 32 and the control module 18 further causes the surgical system 10 to alert a surgeon that a change in viscosity of the material being aspirated has been detected indicating that the handpiece 24 has moved from a material of a first viscosity to a material of a second viscosity.
G08B 21/00 - Alarmes réagissant à une seule condition particulière, indésirable ou anormale, et non prévues ailleurs
A61M 1/00 - Dispositifs de succion ou de pompage à usage médicalDispositifs pour retirer, traiter ou transporter les liquides du corpsSystèmes de drainage
A61F 9/007 - Procédés ou dispositifs pour la chirurgie de l'œil
A phacoemulsification system includes a phacoemulsification handpiece having a horn coupled to a transducer configured to convert alternating current into mechanical oscillation of the horn. The phacoemulsification handpiece further includes a phacoemulsification needle attached to the horn. The phacoemulsification needle vibrates by oscillation of the horn, to provide for mechanical cutting of tissue and inducing cavitation proximate a tip of the phacoemulsification needle. The phacoemulsification system further includes a control system with associated drive circuitry in connection with the transducer of the phacoemulsification handpiece. The control system is configured to adjust an operating frequency of the transducer to increase or decrease a mechanical cutting performance and a cavitational-induced performance of the phacoemulsification needle.
A61F 9/00 - Procédés ou dispositifs pour le traitement des yeuxDispositifs pour mettre en place des verres de contactDispositifs pour corriger le strabismeAppareils pour guider les aveuglesDispositifs protecteurs pour les yeux, portés sur le corps ou dans la main
An aspiration flow control device includes a housing having at least one vacuum port, at least one aspiration port, and an ejection port. The at least one vacuum port is adapted to be connected to a vacuum source, and the aspiration port is adapted to be connected to an aspiration line for receiving fluids from a surgical site. The device further includes a rotating structure having at least three vanes, which structure is configured to rotate within the housing. The at least three vanes divide an enclosed volume within the housing into at least three rotating fluid collection chambers. During rotation of the rotating structure, at least one fluid collection chamber is in communication with at least one vacuum port and the aspiration port through which fluid is received, and at least one other fluid collection chamber is simultaneously in communication with the ejection port through which fluid is expelled.
A61M 1/00 - Dispositifs de succion ou de pompage à usage médicalDispositifs pour retirer, traiter ou transporter les liquides du corpsSystèmes de drainage
An ophthalmic surgical system utilizes a needle through which fluid is aspirated from a surgical site, and a sleeve coaxially received over the needle to define a flow passage between the sleeve and needle through which fluid is communicated to the surgical site. The system further includes a container that provides an adjustable infusion pressure for urging the flow of irrigation fluid to the surgical site. An aspiration pump urges aspiration of fluid from the surgical site, and a sensor detects the rate of aspiration flow. A controller is configured to calculate an intraocular eye pressure based on the infusion pressure and a pressure drop due to a resistance to the flow rate, which flow includes the sensed flow rate and a predicted leakage selected from a look-up table based on a size of the needle, a size of a sleeve, and a size of an incision through which the needle and the sleeve are placed.
A61M 37/00 - Autres appareils pour introduire des agents dans le corpsPercutanisation, c.-à-d. introduction de médicaments dans le corps par diffusion à travers la peau
62.
System for operating and controlling a pneumatically driven vitrectomy probe
A pneumatically driven vitrectomy probe system includes a movable member disposed within a cylinder to define an enclosed pressure chamber, which has an inlet and an outlet. A pressure transducer senses the pressure level within the enclosed pressure chamber, and a valve communicates pressurized air to the inlet of the enclosed pressure chamber based on the pressure level. A displacement device coupled to the movable member extends and retracts the movable member within the enclosed pressure chamber, to respectively increase and decrease the pressure level of pressurized air communicated via the chamber outlet. The pressurized air is communicated to enclosed volume within a pneumatically activated vitrectomy probe, which includes a hollow inner cutting member disposed within the hollow outer member. Upon extension of the displacement member, the resulting increase in pressure level of the pressurized air in the enclosed volume acts against the biasing spring to move the hollow inner cutting member, to cut vitreous material extending within the hollow outer member.
The invention includes a device for inserting a medicament within a body cavity of a mammal, and a cartridge for containing the medicament within the device, where the cartridge includes a housing, a retractable chamber for containing medicament disposed within the housing, and a substantially stationary member disposed within the barrel of the retractable chamber, where upon activation of the device, the retractable chamber is retracted about the substantially stationary member, thereby depositing medicament within the body cavity.
A method for managing a plurality of commercial website accounts maintained by a supplier of goods or services includes receiving a structure via a first computer screen, where the structure specifies a relationship between a first one of the plurality of commercial website accounts and a second one of the plurality of commercial website accounts, so that the first one of the plurality of website accounts is configured to be a parent account of the second of the plurality of website accounts defining a child account; linking the child account and the parent account in accordance with the received structure in response to a command received via the first computer screen; receiving a rule that regulates a purchase of goods or services by a user of the child account via a second computer screen, where the received rule specifies an action associated with a user of the parent account; automatically detecting that the user of the child account has placed an order at the commercial website; and processing the order in accordance with the rule and the structure.
A brimonidine (5-bromo-6-(2-imidazolidinylideneamino)quinoxaline) pamoate polymorph exhibits characteristics disclosed herein. The brimonidine pamoate polymorph is included in a composition, device, or implant for use in the treatment or control of elevated intraocular pressure or in the neuroprotection of components of a neurological tissue to prevent progressive degeneration of such components. In particular, such a composition, device, or implant can be used to provide neuroprotection to cells and components of the optic nerve system.
A61K 31/495 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec deux azote comme seuls hétéro-atomes d'un cycle, p. ex. pipérazine
66.
Eye measurement apparatus and methods of using same
An apparatus for measuring a subject's eye having an instrument axis, comprising a slit projector for projecting slits of light, at least one sensor. The apparatus being adapted to form a first image of light from a first slit on the at least one sensor after the light scatters from the eye along a first pathway. The apparatus adapted to form a second image of light from the first slit on the at least one sensor after the light scatters from the eye along a second pathway. The apparatus comprising a processor operatively coupled to receive the first image and the second image, the processor adapted to perform a projective transformation of the second image and to combine data from the first image and the second image, after it is transformed, to form a third image.
A61B 3/10 - Appareils pour l'examen optique des yeuxAppareils pour l'examen clinique des yeux du type à mesure objective, c.-à-d. instruments pour l'examen des yeux indépendamment des perceptions ou des réactions du patient
A61B 3/00 - Appareils pour l'examen optique des yeuxAppareils pour l'examen clinique des yeux
67.
Method and apparatus for making and processing aberration measurements
A method for determining a centroid coordinate of an image spot, comprising a) determining a search region having a border, b) identifying a first pixel in the search region, the pixel having a first intensity value, c) determining an upper threshold intensity value greater than the first intensity value, d) searching for a second pixel within the search region having an intensity value that is greater than the upper threshold intensity value, and e) upon finding the second pixel, designating the first pixel an integration region center.
A composition comprises besifloxacin in an amount effective for treating or controlling an infection caused by an antibiotic-resistant bacterium. Such a composition can be administered to a subject for the treatment or control of bacterial conjunctivitis caused bay an antibiotic-resistant bacterium.
A61K 31/55 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
69.
Bupropion hydrobromide and therapeutic applications
A multi-chip package is presented which includes a substrate, a lower semiconductor, an upper semiconductor chip, metal wires, an encapsulant, and mounting units. The substrate has electrode terminals on an upper surface and ball lands on a lower surface. The lower semiconductor chip is placed face-down on the substrate. The lower semiconductor chip has first bonding pads, first connectors and metal patterns. The upper semiconductor chip is placed face-down type on the back surface of the lower semiconductor chip. The upper semiconductor has second bonding pads and second connectors. The metal wires electrically the lower semiconductor chip to the substrate. The encapsulant seals the substrate, the lower semiconductor chip, the upper semiconductor chip and the metal wires. The mounting units are on the lower surface of the substrate.
A61K 31/137 - Arylalkylamines, p. ex. amphétamine, épinéphrine, salbutamol, éphédrine
C07C 225/10 - Composés contenant des groupes amino et des atomes d'oxygène, liés par des liaisons doubles, liés au même squelette carboné, au moins un des atomes d'oxygène, liés par des liaisons doubles, ne faisant pas partie d'un groupe —CHO, p. ex. aminocétones ayant des groupes amino liés à des atomes de carbone acycliques du squelette carboné le squelette carboné étant saturé et contenant des cycles avec des atomes d'oxygène, liés par des liaisons doubles, liés à des atomes de carbone ne faisant pas partie de cycles
72.
Memory module with vertically accessed interposer assemblies
A memory module with attached transposer and interposers to provide additional surface area for the placement of memory devices is disclosed. The memory module includes a memory board with a first surface, a second surface and an edge with a set of electrical contacts. A transposer is attached to each surface of the memory board, and an interposer is attached to each transposer on the opposite surface of the transposer from the memory board. The interposer has space to allow placement of memory devices on both a first surface between the interposer and the memory board, and on a second surface of the interposer away from the memory board.
An ophthalmic composition comprising one or more antimicrobial components and a dipeptide. The dipeptide comprises a glycine moiety and another amino acid moiety other than glycine. The ophthalmic compositions include contact lens care solutions for cleaning and disinfecting contact lenses.
A01N 37/18 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés organiques comportant un atome de carbone possédant trois liaisons à des hétéro-atomes, avec au plus deux liaisons à un halogène, p. ex. acides carboxyliques contenant le groupe —CO—N, p. ex. amides ou imides d'acide carboxyliqueLeurs thio-analogues
Polysiloxanes having vinyl or epoxy functionality. The polysiloxanes are used to form polymer-based materials having properties particularly suited for biomedical device applications. The polysiloxanes are of general formula I:
m and n are integers with an m:n ratio from 30:1 to 3:1.
C08G 77/00 - Composés macromoléculaires obtenus par des réactions créant dans la chaîne principale de la macromolécule une liaison contenant du silicium, avec ou sans soufre, azote, oxygène ou carbone
75.
Ophthalmic compositions with an amphoteric surfactant and hyaluronic acid
Ophthalmic compositions that comprise 0.1 ppm to 10 ppm of a cationic antimicrobial component selected from the group consisting of biguanides, polymeric biguanides, quaternium ammonium compounds and any one mixture thereof; 0.005 wt. % to 0.15 wt. % of hyaluronic acid; and 0.01 wt. % to 1.0 wt. % of an amphoteric surfactant of general formula I
8alkylene optionally substituted with hydroxyl. The invention is also direct to the use of the ophthalmic compositions to clean and disinfect contact lenses, and in particular, soft, silicone hydrogel contact lenses.
An ophthalmic device is disclosed that is a polymerization product of a monomeric mixture comprising (a) a major amount of a non-silicone-containing hydrophilic monomer; (b) a hydrophobic monomer; and (c) a crosslinking agent, wherein the ophthalmic device has an equilibrium water content of at least about 70 weight percent and further wherein the ophthalmic device has an evaporative dehydration barrier layer on the surface thereof. A method for the mitigation of evaporative corneal dehydration employing the high water content ophthalmic device is also disclosed.
C08F 20/00 - Homopolymères ou copolymères de composés contenant un ou plusieurs radicaux aliphatiques non saturés, chaque radical ne contenant qu'une seule liaison double carbone-carbone et un seul étant terminé par un seul radical carboxyle ou un sel, anhydride, ester, amide, imide ou nitrile
77.
Naphthyridine derivatives as potassium channel modulators
This invention provided compounds of formula I
where W and Z are, independently, CH or N, and where other substituents are defined herein. Such compounds are potassium channel modulators.
The invention also provides a composition comprising a pharmaceutically acceptable carrier or excipient and at least one of the following: a pharmaceutically effective amount of a compound of formula I; a pharmaceutically acceptable salt of a compound of formula I; a pharmaceutically acceptable ester of a compound of formula I. The invention also provides a method of preventing or treating a disease or disorder which is affected by activities of potassium channels, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula I or a salt or ester or solvate thereof.
A61K 31/505 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime
C07D 401/00 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote
C07D 403/00 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe
C07D 405/00 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle
C07D 409/00 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre comme uniques hétéro-atomes du cycle
C07D 411/00 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'oxygène et de soufre comme uniques hétéro-atomes du cycle
C07D 413/00 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle
C07D 417/00 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe
C07D 419/00 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote, d'oxygène et de soufre comme uniques hétéro-atomes du cycle
78.
Method of forming a biomedical device including an ophthalmic device
A method is provided of forming a biomedical device in a casting mold which has an anterior mold section and a posterior mold section, wherein one of the mold sections includes a plurality of radially extending ribs and the remaining mold section includes an annular shoulder for engaging an outer end of the ribs to define a mold cavity. The method includes engaging the mold sections along a peripheral seal of the mold cavity and a plurality of circumferentially spaced contact points on a shoulder of one of the mold sections. Cured excess material bonds to the ribs of the one mold section and provides repeatable retention and location of the excess material after formation of the biomedical device.
In an aspiration flow measurement system, a flow channel is provided for receiving an aspiration fluid flow therethrough. The flow measurement system further includes an aspiration flow measurement chamber and a flow sensor that is configured to generate a raw signal indicative of the rate of fluid flow through the flow channel. A control system is configured to monitor the signals indicating the flow through the flow measurement chamber, and to determine when a value of the raw signal is indicative of a disruption caused by the presence of an air bubble, wherein the control system generates a filtered signal of the flow rate that is exclusive of any signal values that are indicative of a disruption.
G01F 1/74 - Dispositifs pour la mesure du débit d'un matériau fluide ou du débit d'un matériau solide fluent en suspension dans un autre fluide
A61M 1/00 - Dispositifs de succion ou de pompage à usage médicalDispositifs pour retirer, traiter ou transporter les liquides du corpsSystèmes de drainage
A dental appliance for prevention of Bruxism includes a U-shaped buccal strap having opposing right and left aft end portions. A right bite pad assembly is slidingly connected to and completely encloses the right aft end portion of the buccal strap. A left bite pad assembly is slidingly connected to and completely encloses the left aft end portion of the buccal strap. The right bite pad assembly can include a right upper bite surface member for contacting right upper molars of a wearer and a right lower bite surface member for contacting right lower molars of the wearer. The left bite pad assembly can include a left upper bite surface member for contacting left upper molars of a wearer and a left lower bite surface member for contacting left lower molars of the wearer. A right channel extends through the right upper bite surface member and the right lower bite surface member. A left channel extends through the left upper bite surface member and the left lower bite surface member. The right channel receives the right aft end portion of the buccal strap, and the left channel receives the left aft end portion of the buccal strap.
A flow measurement device 100 is provided that includes an electrode terminal chamber 102 with an inlet 104 in communication with a flow channel 108 for receiving fluid and viscoelastic material aspirated from a surgical site, and an outlet 106 that tapers into a flow channel 108. The outlet 108 has a taper angle that is sufficient to smooth flow and cause viscoelastic material entering the electrode terminal chamber 102 to flow substantially within a center portion of the chamber and through the outlet 106. The electrode terminal chamber 102 further includes first and second electrode terminals 130 and 140 disposed on generally opposite sides of the electrode terminal chamber 102 in a spaced-apart manner. The first and second electrode terminals 130 and 140 are positioned a distance from the center of the chamber 102 that is sufficient to substantially avoid contact between the terminals and viscoelastic materials flowing through the chamber 102.
A61M 1/00 - Dispositifs de succion ou de pompage à usage médicalDispositifs pour retirer, traiter ou transporter les liquides du corpsSystèmes de drainage
Methods and apparatus for facilitating determination of centroids of image spots in an image containing an array of image spots generated by an aberrometer, the image comprising a first plurality of pixels each pixel having a corresponding intensity value, the method comprising calculating an average intensity value for a second plurality of pixels in a perimeter around a pixel, the average calculated using a subset of the second plurality exclusive of at least a portion of the pixels in the perimeter.
A61B 3/10 - Appareils pour l'examen optique des yeuxAppareils pour l'examen clinique des yeux du type à mesure objective, c.-à-d. instruments pour l'examen des yeux indépendamment des perceptions ou des réactions du patient
An air bubble separator is provided for ophthalmic surgical systems, which includes a housing 102 having a diagonally-oriented flow channel 110 and a vertically-oriented flow channel 130 adjoining the diagonally oriented channel. The diagonally-oriented flow channel 110 has a downstream portion 112 disposed downstream of the vertically-oriented flow channel 130, and an upstream portion 118 disposed upstream of the vertically-oriented flow channel 130. The downstream portion 112 of the diagonally-oriented flow channel 110 has a cross-sectional area 114 that is greater than that of the upstream portion 118. The downstream portion's cross-sectional area 114 is greater than the upstream portion's cross-sectional area 124 by an amount or percentage that is sufficient to slow fluid flow through the diagonally-oriented flow channel 110, so as to cause air within the fluid to rise and flow into the vertically-oriented flow channel 130.
G01F 15/08 - Séparateurs d'air ou de gaz en combinaison avec des compteurs de liquidesSéparateurs de liquide en combinaison avec des compteurs de gaz
A61M 1/00 - Dispositifs de succion ou de pompage à usage médicalDispositifs pour retirer, traiter ou transporter les liquides du corpsSystèmes de drainage
An interferometric axial eye length measurement apparatus having a light source adapted to produce a beam of partially coherent light, a first mirror and a second mirror disposed in the reference arm, and a processor adapted to control at least the second mirror such that a corneal interference peak and a second interference peak have a non-zero separation. There is at least one variable delay optical element having a delay signal, wherein the delay signal corresponding to a region between the corneal interference peak and second interference peak is substantially linear.
The invention includes a cartridge for use in a device for inserting a medicament within a body cavity of a mammal, the cartridge including a housing, a retractable chamber disposed within the housing and having a lumen having a uniform cross-section sized to contain the medicament therein, a substantially stationary member disposed within the lumen of the retractable chamber and having a uniform cross-section sized to provide a sliding fit within the lumen suitable to provide for retraction of the retractable chamber about the substantially stationary member upon actuation of the device; and means for retracting the retractable chamber about the substantially stationary member while maintaining the substantially stationary member in a substantially stationary position upon actuation of the device.
A method for modifying the refractive index of an optical, polymeric material. The method comprises irradiating select regions of the optical, polymeric material with a focused, visible or near-IR laser having a pulse energy from 0.05 nJ to 1000 nJ. The irradiation results in the formation of refractive optical structures, characterized by a change in refractive index, exhibit little or no scattering loss, and exhibit no significant differences in the Raman spectrum with respect to the non-irradiated optical, polymeric material. The method can be used to modify the refractive index of an intraocular lens following the surgical implantation of the intraocular lens in a human eye. The invention is also directed to an optical device comprising refractive optical structures, wherein the refractive structures are characterized by a change in refractive index, exhibit little or no scattering loss, and exhibit no significant differences in the Raman spectrum with respect to the non-irradiated optical, polymeric material.
The invention includes a device for inserting a medicament within a body cavity of a mammal, the device including a cartridge for containing the medicament therein, the cartridge including a housing, a retractable chamber disposed within the housing and having a lumen, a substantially stationary member disposed within the lumen of the retractable chamber and having a uniform cross-section sized to provide a sliding fit within the lumen to provide for retraction of the retractable chamber about the substantially stationary member upon actuation of the device, and means for retracting the retractable chamber about the substantially stationary member while maintaining the substantially stationary member in a substantially stationary position upon actuation of the device; the device further including means for activating the means for retracting the retractable chamber.
This invention is a composition comprising a cyclic siloxane, a silicone occlusive fluid, a silicone occlusive gel, and a silicone resin powder. The composition is useful for wound healing.
A61K 31/34 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à cinq chaînons avec un oxygène comme seul hétéro-atome d'un cycle, p. ex. isosorbide
Silicone hydrogels formed from a hydrated polymerization product of a monomer mixture comprising (a) a major amount of a non-silicone-containing hydrophilic monomer; and (b) a minor amount of a silicone-containing monomer, wherein the hydrogel has a water content of greater than 50 weight percent are disclosed.
The invention includes an actuator for actuating a device for inserting a medicament within a body cavity of a mammal, the actuator including a handle case having a proximal portion for gripping and a distal portion including means for attaching the actuator to a cartridge for containing medicament, and means for creating a proximal to distal linear motion with respect to the handle case, wherein the cartridge includes a retractable chamber for containing the medicament disposed therein, a substantially stationary member and means for retracting the retractable chamber about the substantially stationary member while maintaining the substantially stationary member in a substantially stationary position.
An ophthalmic device forming system includes an inspection station configured to receive a plurality of ophthalmic devices, a fluid supply fluidly connected to the inspection station, the fluid supply containing a working fluid, and a heat source fluidly connected between the fluid supply and the inspection station. The heat source includes a housing, a transfer element, and a low pressure gas region defined by the housing adjacent to the transfer element.
A mold assembly for the manufacture of at least one ophthalmic device used in or on the eye is disclosed. The mold assembly includes a mateable pair of mold parts wherein at least one of the mold parts comprises at least an oxygen-absorbing mold material and an oxygen scavenger composition containing (i) an oxygen scavenging polymer comprising a polymer backbone and one or more substituted or unsubstituted cyclic olefinic groups covalently linked to the polymer backbone; and (ii) an oxygen scavenging catalytic amount of a transition metal catalyst.
A packaging system for the storage of an ionic, hydrogel contact lens employs an aqueous packaging solution including a phosphorylcholine polymer. Preferably, the solution has an osmolality of at least about 200 mOsm/kg, a pH of about 6 to about 8 and is heat sterilized.
The invention relates to a method for heat sealing a lidstock (9) to a container (1) for a blister package, the container having a top surface comprising a substantially flat sealing flange (3) surrounding a blister (2) and a lip (4) having at least one raised surface (6), the method comprising the steps of a) locating the lidstock on the top surface; b) providing a first seal between the lidstock and the at least one raised surface of the lip with a first heat sealing tool (11); c) providing a second hermetic seal between the lidstock and the sealing flange surrounding the blister with a second heat sealing tool. The invention also relates to a package for storing a hydrophilic contact lens comprising a lip having at least one raised surface and a removable lidstock sealed to a sealing flange and to the at least one raised surface. Also disclosed is an apparatus for heat sealing the lidstock to the container.
A61K 9/52 - Préparations en capsules, p. ex. de gélatine, de chocolat du type à libération prolongée ou discontinue
A61K 9/54 - Préparations en capsules, p. ex. de gélatine, de chocolat du type à libération prolongée ou discontinue contenant des particules distinctes avec des revêtements de différentes épaisseurs ou de différents matériaux
Crosslink agents used to copolymerize at least one hydrophilic monomer with at least one lens monomer typically used to prepare polymeric materials for ophthalmic lenses. The crosslink agents have a relatively high selectivity for the hydrophilic monomer and limited reactivity with the crosslink agent used to polymerize the lens monomer. Accordingly, the invention is also directed to a hydrophilic crosslinked polymer that comprises at least two monomeric units and at least two different crosslink units. The use of the dual crosslink system provides an improved means to control the final chemical, physical and structural characteristics of the resulting polymer.
C07C 69/602 - Esters d'acides dicarboxyliques avec plusieurs liaisons doubles carbone-carbone
C07C 211/36 - Composés contenant des groupes amino liés à un squelette carboné ayant des groupes amino liés à des atomes de carbone de cycles autres que des cycles aromatiques à six chaînons d'un squelette carboné saturé contenant au moins deux groupes amino liés au squelette carboné
97.
Silicone hydrogel with composite hydrophilic and silicone polymers prepared with selective crosslink agents
A synthetic route to polymers comprised of at least two monomers each with a very different reactivity ratio by using a corresponding crosslink agent for each monomer. Novel crosslink agents are described that provide for the copolymerization of at least one hydrophilic monomer with at least one lens monomer typically used to prepare materials for ophthalmic lenses. The new crosslink agents have a relatively high selectivity for the hydrophilic monomer and limited reactivity with the crosslink agent used to polymerize the lens monomer.
G02B 1/04 - Éléments optiques caractérisés par la substance dont ils sont faitsRevêtements optiques pour éléments optiques faits de substances organiques, p. ex. plastiques
C08G 77/00 - Composés macromoléculaires obtenus par des réactions créant dans la chaîne principale de la macromolécule une liaison contenant du silicium, avec ou sans soufre, azote, oxygène ou carbone
A61B 3/10 - Appareils pour l'examen optique des yeuxAppareils pour l'examen clinique des yeux du type à mesure objective, c.-à-d. instruments pour l'examen des yeux indépendamment des perceptions ou des réactions du patient
A61B 18/18 - Instruments, dispositifs ou procédés chirurgicaux pour transférer des formes non mécaniques d'énergie vers le corps ou à partir de celui-ci par application de radiations électromagnétiques, p. ex. de micro-ondes
99.
Method for modifying the refractive index of ocular tissues
A method for modifying the refractive index of ocular tissues. The method comprises irradiating select regions of ocular tissue with a visible or near-IR laser. The irradiation results in the formation of structures in the ocular tissue, characterized by a change in refractive index, and which exhibit little or no scattering loss.
A61B 18/18 - Instruments, dispositifs ou procédés chirurgicaux pour transférer des formes non mécaniques d'énergie vers le corps ou à partir de celui-ci par application de radiations électromagnétiques, p. ex. de micro-ondes
100.
Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
This invention provides potassium channel modulators which are compounds of formula I
where the moiety
A
2 as defined below, and containing zero or one ring nitrogen atom; and where other substituents are defined herein.
The invention also provides a composition comprising a pharmaceutically acceptable carrier and at least one of the following: i) a pharmaceutically effective amount of a compound of formula I and ii) a pharmaceutically acceptable salt, ester, or prodrug thereof. The invention also provides a method of preventing or treating a disease or disorder which is affected by activities of potassium channels, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula I or a salt, ester, or prodrug thereof.
brevets